{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T05:29:42Z","timestamp":1732253382081,"version":"3.28.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,21]]},"DOI":"10.7759\/cureus.74172","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T19:08:30Z","timestamp":1732216110000},"source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of Anti-tumor Necrosis Factor Drugs on Hidradenitis Suppurativa: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Rojina","family":"Samifanni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Gatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Kabore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariangela","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manal","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theofanis F","family":"Kollias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy A","family":"Clunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21060","article-title":"Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum","volume":"187","author":"Navrazhina K","year":"2022","unstructured":"Navrazhina K, Frew JW, Grand D, et al.. Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum. Br J Dermatol. 2022, 187:223-33. 10.1111\/bjd.21060","journal-title":"Br J Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.04.067","article-title":"Hidradenitis suppurativa (HS) is associated with low socioeconomic status (SES): a cross-sectional reference study","volume":"75","author":"Deckers IE","year":"2016","unstructured":"Deckers IE, Janse IC, van der Zee HH, Nijsten T, Boer J, Horv\u00e1th B, Prens EP. Hidradenitis suppurativa (HS) is associated with low socioeconomic status (SES): a cross-sectional reference study. J Am Acad Dermatol. 2016, 75:755-9. 10.1016\/j.jaad.2016.04.067","journal-title":"J Am Acad Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0747","article-title":"Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors","volume":"89","author":"Haslund P","year":"2009","unstructured":"Haslund P, Lee RA, Jemec GB. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. Acta Derm Venereol. 2009, 89:595-600. 10.2340\/00015555-0747","journal-title":"Acta Derm Venereol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.139932","article-title":"Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-\u03b1 therapy","volume":"5","author":"Lowe MM","year":"2020","unstructured":"Lowe MM, Naik HB, Clancy S, et al.. Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-\u03b1 therapy. JCI Insight. 2020, 5:19. 10.1172\/jci.insight.139932","journal-title":"JCI Insight"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.05.033","article-title":"Hidradenitis suppurativa is characterized by dysregulation of the Th17:Treg cell axis, which is corrected by anti-TNF therapy","volume":"137","author":"Moran B","year":"2017","unstructured":"Moran B, Sweeney CM, Hughes R, et al.. Hidradenitis suppurativa is characterized by dysregulation of the Th17:Treg cell axis, which is corrected by anti-TNF therapy. J Invest Dermatol. 2017, 137:2389-95. 10.1016\/j.jid.2017.05.033","journal-title":"J Invest Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15160","article-title":"Anti-TNF-\u03b1 therapy modulates mTORC1 signalling in hidradenitis suppurativa","volume":"33","author":"Balato A","year":"2019","unstructured":"Balato A, Caiazzo G, Annunziata MC, Marasca C, Scala E, Cacciapuoti S, Fabbrocini G. Anti-TNF-\u03b1 therapy modulates mTORC1 signalling in hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2019, 33:e43-5. 10.1111\/jdv.15160","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S93619","article-title":"Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa","volume":"9","author":"Fotiadou C","year":"2016","unstructured":"Fotiadou C, Vakirlis E, Ioannides D. Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa. Clin Cosmet Investig Dermatol. 2016, 9:367-72. 10.2147\/CCID.S93619","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball AB","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, et al.. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016, 375:422-34. 10.1056\/NEJMoa1504370","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19863","article-title":"Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study","volume":"185","author":"Prens LM","year":"2021","unstructured":"Prens LM, Bouwman K, Aarts P, et al.. Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study. Br J Dermatol. 2021, 185:177-84. 10.1111\/bjd.19863","journal-title":"Br J Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15286","article-title":"Treatment of hidradenitis suppurativa with certolizumab pegol during pregnancy","volume":"60","author":"Wohlmuth-Wieser I","year":"2021","unstructured":"Wohlmuth-Wieser I, Alhusayen R. Treatment of hidradenitis suppurativa with certolizumab pegol during pregnancy. Int J Dermatol. 2021, 60:e140-1. 10.1111\/ijd.15286","journal-title":"Int J Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.72","article-title":"Treatment of hidradenitis suppurativa with etanercept injection","volume":"146","author":"Adams DR","year":"2010","unstructured":"Adams DR, Yankura JA, Fogelberg AC, Anderson BE. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol. 2010, 146:501-4. 10.1001\/archdermatol.2010.72","journal-title":"Arch Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-0488.16.05530-9","article-title":"Use of biological treatments in patients with hidradenitis suppurativa","volume":"152","author":"Martin-Ezquerra G","year":"2017","unstructured":"Martin-Ezquerra G, Masferrer E, Pujol RM. Use of biological treatments in patients with hidradenitis suppurativa. G Ital Dermatol Venereol. 2017, 152:373-8. 10.23736\/S0392-0488.16.05530-9","journal-title":"G Ital Dermatol Venereol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac096","article-title":"Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies","volume":"188","author":"Schell SL","year":"2023","unstructured":"Schell SL, Cong Z, Sennett ML, et al.. Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies. Br J Dermatol. 2023, 188:407-19. 10.1093\/bjd\/ljac096","journal-title":"Br J Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10071.x","article-title":"Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer?","volume":"164","author":"Boer J","year":"2011","unstructured":"Boer J, Nazary M. Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer?. Br J Dermatol. 2011, 164:170-5. 10.1111\/j.1365-2133.2010.10071.x","journal-title":"Br J Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial","volume":"157","author":"Glatt S","year":"2021","unstructured":"Glatt S, Jemec GB, Forman S, et al.. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial. JAMA Dermatol. 2021, 157:1279-88. 10.1001\/jamadermatol.2021.2905","journal-title":"JAMA Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial","volume":"152","author":"Tzanetakou V","year":"2016","unstructured":"Tzanetakou V, Kanni T, Giatrakou S, et al.. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol. 2016, 152:52-9. 10.1001\/jamadermatol.2015.3903","journal-title":"JAMA Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/303796-effectiveness-of-anti-tumor-necrosis-factor-drugs-on-hidradenitis-suppurativa-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T19:08:31Z","timestamp":1732216111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/303796-effectiveness-of-anti-tumor-necrosis-factor-drugs-on-hidradenitis-suppurativa-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.74172","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,21]]}}}